7.46
-1.84%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lanzhou Foci Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002644.SZ. It has been listed since 22 December 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥915.5m and net income of CN¥49.2m. At that date it held total assets of CN¥2.55bn and shareholders' equity of CN¥1.83bn.
Lanzhou Foci Pharmaceutical Co., Ltd. engages in raw material research, modern formulations production, and extraction of traditional Chinese medicine. The company is headquartered in Lanzhou, Gansu. The company went IPO on 2011-12-22. The Company’s main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The firm distributes its products under the brand names Foci, Baolu and Mianshan. The firm is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Dec 2011
- Employees
- 1,404
- Website
- fczy.com ↗
Leadership
Pay as last reported
- Mr. Xiaodong ShanChairman of the Board, since 2024
- Ms. Jinfeng YueChief Financial Officer
- Mr. Shuangxi QianGeneral Manager, Director, since 2024
- Mr. Guolin ChaiDeputy General ManagerCN¥382,500
- Mr. Xiaoyun FengDeputy General ManagerCN¥360,500
- Mr. Yingming ZhangDeputy General Manager
- Mr. Junhui WangSecretary of the Board
- Mr. Xinhai WangDirector, since 2017
- Ms. Huayun HuIndependent Director
- Mr. Hongwen JiaIndependent Director
- Mr. Zhigang LiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lanzhou Foci Pharmaceutical employs 1,404 full-time staff for research and production.
- The company produces Liuwei Dihuang pills and other Chinese patent drugs.
- Foci brand products are distributed domestically and internationally.
Weaknesses
- The company's main products include pills, tablets, and granules only.
- Lanzhou Foci Pharmaceutical has no presence in international markets beyond distribution.
- The firm relies on traditional Chinese medicine extraction methods.
Opportunities
- Expansion into large health products like Ejiao and Ejiao loafs.
- Growing demand for Chinese patent drugs in domestic markets.
- Potential for overseas market growth in pharmaceuticals.
Threats
- Competition from other pharmaceutical companies in China.
- Regulatory changes affecting traditional Chinese medicine.
- Dependence on raw material supply for production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.